Acuta Capital Partners 13F annual report

Acuta Capital Partners is an investment fund managing more than $119 billion ran by Scott Smith. There are currently 31 companies in Mr. Smith’s portfolio. The largest investments include Ocular Therapeutix Inc and Enliven Therapeutics Inc, together worth $28.2 billion.

Limited to 30 biggest holdings

$119 billion Assets Under Management (AUM)

As of 7th August 2024, Acuta Capital Partners’s top holding is 2,771,130 shares of Ocular Therapeutix Inc currently worth over $19 billion and making up 16.0% of the portfolio value. Relative to the number of outstanding shares of Ocular Therapeutix Inc, Acuta Capital Partners owns more than approximately 0.1% of the company. In addition, the fund holds 397,698 shares of Enliven Therapeutics Inc worth $9.29 billion. The third-largest holding is Vaxcyte worth $8.34 billion and the next is Dyne Therapeutics worth $7.5 billion, with 212,500 shares owned.

Currently, Acuta Capital Partners's portfolio is worth at least $119 billion. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.

Careers at Acuta Capital Partners

The Acuta Capital Partners office and employees reside in Redwood City, California. According to the last 13-F report filed with the SEC, Scott Smith serves as the Chief Operating Officer at Acuta Capital Partners.

Recent trades

In the most recent 13F filing, Acuta Capital Partners revealed that it had opened a new position in Corbus Pharmaceuticals Holdi and bought 64,500 shares worth $2.92 billion.

The investment fund also strengthened its position in Ocular Therapeutix Inc by buying 135,843 additional shares. This makes their stake in Ocular Therapeutix Inc total 2,771,130 shares worth $19 billion. Ocular Therapeutix Inc soared 79.4% in the past year.

On the other hand, there are companies that Acuta Capital Partners is getting rid of from its portfolio. Acuta Capital Partners closed its position in Applied Therapeutics on 14th August 2024. It sold the previously owned 792,000 shares for $5.39 billion. Scott Smith also disclosed a decreased stake in Rocket Pharmaceuticals Inc by 0.2%. This leaves the value of the investment at $5.39 billion and 250,370 shares.

One of the smallest hedge funds

The two most similar investment funds to Acuta Capital Partners are Dc Investments Management and Duncan Williams Asset Management. They manage $119 billion and $119 billion respectively.

Scott Smith investment strategy

Acuta Capital Partners’s portfolio is diversified across 2 sectors. Currently, their heaviest sector is Health Care — making up 61.0% of the total portfolio value. The fund focuses on investments in the United States as 51.6% of the portfolio companies are based in the United States.

The majority of the companies in the fund’s portfolio are small-cap stocks. Stocks with a size of more than $100 million in market cap make up 13% of the total holdings value. On the other hand, large-cap stocks make up only 3.2% of the portfolio. The average market cap of the portfolio companies is close to $1.45 billion.

The complete list of Acuta Capital Partners trades based on 13F SEC filings

These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.

Security	Shares Owned	Value	Allocation
Ocular Therapeutix Inc	5.15% 2,771,130	$18,954,529,000	15.98%
Enliven Therapeutics Inc	0.40% 397,698	$9,294,202,000	7.84%
Vaxcyte, Inc.	5.31% 110,400	$8,336,304,000	7.03%
Dyne Therapeutics, Inc.	15.18% 212,500	$7,499,125,000	6.32%
Praxis Precision Medicines I	1.31% 164,431	$6,800,866,000	5.73%
Crinetics Pharmaceuticals Inc	72.37% 135,141	$6,052,965,000	5.10%
Rocket Pharmaceuticals Inc	23.38% 250,370	$5,390,466,000	4.54%
Applied Therapeutics, Inc.	Closed 792,000	$5,385,600,000
Taysha Gene Therapies, Inc.	30.07% 2,330,937	$5,221,299,000	4.40%
Revolution Medicines Inc	7.50% 133,000	$5,161,730,000	4.35%
Insmed Inc	16.82% 72,100	$4,830,700,000	4.07%
Disc Medicine Inc	Closed 76,800	$4,781,568,000
Celldex Therapeutics Inc.	Closed 109,000	$4,574,730,000
Sarepta Therapeutics Inc	57.14% 27,500	$4,345,000,000	3.66%
Hillevax Inc	Closed 250,609	$4,167,628,000
Tourmaline Bio Inc	3.26% 269,614	$3,467,236,000	2.92%
Agios Pharma	42.41% 78,700	$3,393,544,000	2.86%
Kura Oncology Inc. Common Stock	81.11% 163,000	$3,356,170,000	2.83%
Mersana Therapeutics Inc	23.17% 1,663,000	$3,342,630,000	2.82%
Immunovant Inc	Closed 92,346	$2,983,699,000
Corbus Pharmaceuticals Holdi	Opened 64,500	$2,918,625,000	2.46%
Aadi Biosciences Inc	No change 1,849,402	$2,700,127,000	2.28%
Viridian Therapeutics Inc	No change 199,433	$2,594,623,000	2.19%
Terns Pharmaceuticals Inc	20.60% 369,280	$2,514,797,000	2.12%
Verastem Inc	Closed 207,095	$2,443,721,000
Mereo Biopharma Group Pl-adr	70.15% 677,000	$2,437,200,000	2.05%
Arcellx Inc	22.32% 42,200	$2,329,018,000	1.96%
Helix Acquisition Corp Ii	Opened 177,836	$1,817,484,000	1.53%
Argenx Se	Opened 4,000	$1,720,160,000	1.45%
Lyra Therapeutics, Inc.	Closed 173,320	$1,078,050,000
Ultragenyx Pharmaceutical Inc.	Closed 20,000	$933,800,000
Intra-Cellular Therapies Inc	Closed 13,300	$920,360,000
Trevi Therapeutics, Inc.	Opened 260,000	$774,800,000	0.65%
Celcuity Inc	Opened 45,000	$737,100,000	0.62%
Oric Pharmaceuticals, Inc.	7.69% 96,000	$678,720,000	0.57%
Pliant Therapeutics, Inc.	Opened 46,200	$496,650,000	0.42%
Rapport Therapeutics Inc	Opened 20,000	$465,200,000	0.39%
Newamsterdam Pharma Co Nv	Opened 22,500	$432,225,000	0.36%
Leap Therapeutics Inc	44.94% 195,000	$382,200,000	0.32%
Cellectar Biosciences Inc	50.87% 70,500	$176,250,000	0.15%
No transactions found
Showing first 500 out of 40 holdings